Cerity Partners
AKBA icon

Cerity Partners’s Akebia Therapeutics AKBA Stock Holding History

Cerity Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
+112,117
New +$133K ﹤0.01% 3173

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cerity Partners's AKBA Position: Q2 2026 in Review

Cerity Partners opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 112,117 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #3173 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Cerity Partners held 112,117 shares of Akebia Therapeutics worth $128K as of Q2 2026.
  • Akebia Therapeutics was a new Cerity Partners position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3173 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.